PhRMA chief defends 'alternative' data-sharing plan
This article was originally published in Scrip
Executive Summary
A day after pledging to release clinical trial results in a "responsible" manner – ensuring patient-specific data and confidential corporate information are protected – the head of the US organization representing drug makers defended the new set of data-sharing principles as a better alternative to the "indiscriminant disclosures of companies' nonpublic data" European regulators have proposed, which he said would "risk damaging public health and patient welfare."